Taipei City, Taiwan -- (SBWire) -- 12/28/2015 --Braincure-Biotech.com (ISIN:TW0001327872) reported that in preclinical studies, injections of the protein Artemin promoted the regeneration of damaged sensory nerve cells and produced virtually complete, long-term restoration of sensory and motor function.
Artemin, also known as Neublastin, belongs to a family of proteins, called glial-derived neurotrophic factors, which promote nerve cell survival. The protein is unique because it acts selectively on sensory neurons. In previous preclinical studies, Artemin reversed a number of features of chronic pain associated with peripheral nerve injury.
"Sensory nerves entering the spinal cord have minimal capacity to regenerate and severe injury often results in permanent loss of sensory functions," said Liao Ming, MD, Head of Department of Neurology at Braincure Biotech. "The results of our preclinical studies, showing dramatic, long-term recovery of pain sensation and complex motor skills after Artemin injections, represent an important and novel advance in research efforts in the area of traumatic nerve injury."
In a series of biochemical, molecular and electrophysiology studies, the researchers also demonstrated that Artemin promoted the regeneration of multiple classes of nerve cells back into the spinal cord and the re-establishment of functional connections with their spinal targets.
"These exciting results support further research, as the data suggest that Artemin may have the potential to promote sensory neuronal regeneration and functional recovery following injury. The Artemin program is part of Braincure Biotech's commitment to innovative neurological science and discovery." continued Mr. Ming.
About Braincure Biotech
Braincure-Biotech.com is a state-of-the-art technology research company that uses discoveries in neuroimmunolgy and human genetics to develop novel therapeutics for Alzheimer's disease, other forms of dementia, and mechanistically similar disorders. Braincure Biotech's strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. The goal of the firm is to discover and develop novel, disease modifying therapies for dementia and mechanistically similar disorders. The highly professional and acclaimed team of scientists maintains an innovative and motivating environment in which every employee has the possibility to contribute to our joint success and to grow individually.
For Media Contact:
Company: Braincure-Biotech.com
Address: Taipei Far Eastern Plaza
No. 207, Section 2
Dun Hua South Road,
Taipei 106, Taiwan
Email: media@braincure-biotech.com
